Device Trial Radar · NCT06188247
Pilot-trial Testing Remote Sleep Apnea Evaluation in Patients with Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Dec 1, 2023
Primary completion
Jul 1, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Herlev and Gentofte HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an investigator-initiated virtual (or decentralized) trial that includes a postal parcel (mail-in) containing sensors for SA diagnosis (NightOwl™) and physical activity (SENS Motion), in addition to smart-phone based heart rhythm (FibriCheck) monitoring in participants with paroxysmal or persistent AF. A case-coordinator (the investigators) will manage all participant contacts virtually during the study from inclusion to follow-up.
Conditions
- Atrial Fibrillation
- Sleep Apnea
Interventions
NightOwl home-monitoringDevice
The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Drop-outsTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Herlev and Gentofte Hospital
Gentofte Municipality, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.